- Home
- KALV vs BOE Comparison
KALV vs BOE Comparison
Compare KALV & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- BOE
- Stock Information
- Founded
- KALV N/A
- BOE 2005
- Country
- KALV United States
- BOE United States
- Employees
- KALV N/A
- BOE N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- BOE Trusts Except Educational Religious and Charitable
- Sector
- KALV Health Care
- BOE Finance
- Exchange
- KALV Nasdaq
- BOE Nasdaq
- Market Cap
- KALV 642.3M
- BOE 634.0M
- IPO Year
- KALV N/A
- BOE N/A
- Fundamental
- Price
- KALV $11.41
- BOE $11.28
- Analyst Decision
- KALV Strong Buy
- BOE
- Analyst Count
- KALV 8
- BOE 0
- Target Price
- KALV $24.83
- BOE N/A
- AVG Volume (30 Days)
- KALV 1.1M
- BOE 166.1K
- Earning Date
- KALV 07-10-2025
- BOE 01-01-0001
- Dividend Yield
- KALV N/A
- BOE 7.30%
- EPS Growth
- KALV N/A
- BOE N/A
- EPS
- KALV N/A
- BOE N/A
- Revenue
- KALV N/A
- BOE N/A
- Revenue This Year
- KALV N/A
- BOE N/A
- Revenue Next Year
- KALV N/A
- BOE N/A
- P/E Ratio
- KALV N/A
- BOE N/A
- Revenue Growth
- KALV N/A
- BOE N/A
- 52 Week Low
- KALV $7.30
- BOE $8.80
- 52 Week High
- KALV $15.50
- BOE $10.48
- Technical
- Relative Strength Index (RSI)
- KALV 37.30
- BOE 59.57
- Support Level
- KALV $11.10
- BOE $11.12
- Resistance Level
- KALV $12.63
- BOE $11.29
- Average True Range (ATR)
- KALV 0.89
- BOE 0.09
- MACD
- KALV -0.23
- BOE -0.01
- Stochastic Oscillator
- KALV 31.35
- BOE 96.55
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.